4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple ...
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: GlobeNewswire
4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up to 2 years of follow-upStrong dose response in favor of Phase 3 dose (3E10 vg/eye) continues to be demonstrated4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings, consistent with previous updates, with up to 3.5 years of follow-up4FRONT-1 Phase 3 enrollment continues to exceed initial expectations, with over 200 patients randomized to date; the global 4FRONT-2 Phase 3 clinical trial enrollment remains on track for expected completion in H2 2026 EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- 4DMT to Participate in 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- 4DMT to Participate in 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- 4DMT Appoints Kristian Humer as Chief Financial OfficerGlobeNewswire
- 4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FDMT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WallMarketBeat
FDMT
Earnings
- 11/10/25 - Beat
FDMT
Sec Filings
- 11/19/25 - Form 4
- 11/17/25 - Form 144
- 11/17/25 - Form 8-K
- FDMT's page on the SEC website